An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Jean-Paul Clozel, whose firm Actelion was bought by Johnson & Johnson for $30bn, is back with his new company and a new approach to help save the lives of heart attack patients.
Swiss biotech company Idorsia’s stated mission is to fulfil unmet patient needs with novel therapeutics that big pharma would never dream of attempting to develop, and its Phase III trial of candidate selatogrel certainly ticks both these boxes.
It is developing the fast-acting anti-platelet therapy for patients at high risk of a recurrent acute myocardial infarction (AMI), allowing them to self-administer the drug with an auto-injector when they suspect they are suffering a heart attack.
